3 active not recruiting. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 3 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Blindness: new trials by email Literature Review of Blindness trials Research Report on Blindness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration Ixo-vec, Aflibercept - Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD | Phase 3 | Active not recruiting | Adverum Biotechnologies, Inc. | 311 | 2025-02-28 | 2026-05-22 |
| Oral N-acetylcysteine for Retinitis Pigmentosa N-acetylcysteine, Placebo - Retinitis Pigmentosa | Phase 3 | Active not recruiting | Johns Hopkins University | 485 | 2023-10-11 | 2026-06-15 |
| A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) sepofarsen, Sham - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Active not recruiting | ProQR Therapeutics | 36 | 2019-04-04 | 2022-03-17 |
Eye Diseases (2) · Eye Abnormalities (1) · Eye Diseases, Hereditary (1) · Leber Congenital Amaurosis (1) · Leber Congenital Amaurosis 10 (1) · Meckel Syndrome, Type 4 (1) · Neurologic Manifestations (1) · Optic Atrophy, Hereditary, Leber (1) · Retinal Diseases (1) · Retinitis Pigmentosa (1) · Sensation Disorders (1) · Usher Syndromes (1) · Vision Disorders (1)
Nervous System Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Neurologic Manifestations (2) · Sensation Disorders (2) · Vision Disorders (2) · Abnormalities, Multiple (1) · Cranial Nerve Diseases (1) · Deaf-Blind Disorders (1) · Deafness (1) · Ear Diseases (1)
Acetylcysteine (1) · aflibercept (1) · salicylhydroxamic acid (1)
Adverum Biotechnologies, Inc. (1) · Johns Hopkins University (1) · ProQR Therapeutics (1)
United States (3) · Canada (2) · Germany (2) · Netherlands (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Brazil (1) · France (1) · Italy (1) · Switzerland (1)
Adam Turpcu, PhD (1) · Peter A Campochiaro, MD (1) · Xiangrong Kong (1)
1UG1EY033293 (1), 2018 (1)